San Diego, California, United States · Est. 2014
Mirum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for liver and bile duct diseases.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
By Phase
4 drugs in development
By Therapeutic Area
top 2
R&D Momentum
50/100
Pipeline Velocity
25/100
Trial Completion Rate
83/100
Pipeline Concentration
38/100
Pipeline Freshness
77/100
Strategic Signals
Activity
Last 14 days
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
8-K
Earlier
Details
Company Overview
—
Mkt Cap
$186.4M
Revenue
$222.5M
Cash
Therapeutic Focus
Recent SEC Filings
8-K
8-K
8-K
Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)
Pipeline
Regulatory
Cholbam — CHOLBAM
Application NDA205750 (NDA)
Livmarli — LIVMARLI
Application NDA214662 (NDA)
Livmarli — LIVMARLI
Application NDA219485 (NDA)
8-K
Accession: 0001759425-26-000047
8-K
Accession: 0001759425-26-000044
8-K
Accession: 0001193125-26-275811
Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)
Accession: 001-38981
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)